Loading...

Vital Therapies

DB:10V
Snowflake Description

Adequate balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
10V
DB
$35M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Vital Therapies, Inc., a biotherapeutic company, focuses on developing cell-based therapies for the treatment of acute forms of liver failure. The last earnings update was 2 days ago. More info.


Add to Portfolio Compare Print
  • Vital Therapies has significant price volatility in the past 3 months.
10V Share Price and Events
7 Day Returns
45.5%
DB:10V
-1.4%
DE Biotechs
-0.3%
DE Market
1 Year Returns
-82%
DB:10V
-7%
DE Biotechs
-7.5%
DE Market
10V Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Vital Therapies (10V) 45.5% 737.9% 579.9% -82% -89.7% -
DE Biotechs -1.4% 2.4% -7.3% -7% 45.1% 10.5%
DE Market -0.3% 2.7% 7.5% -7.5% 9.6% 12.4%
1 Year Return vs Industry and Market
  • 10V underperformed the Biotechs industry which returned -7% over the past year.
  • 10V underperformed the Market in Germany which returned -7.5% over the past year.
Price Volatility
10V
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Vital Therapies undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Vital Therapies. This is due to cash flow or dividend data being unavailable. The share price is €0.8295.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Vital Therapies's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Vital Therapies's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:10V PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-0.86
NasdaqGS:VTL Share Price ** NasdaqGS (2019-04-12) in USD $0.83
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 23.84x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 19.55x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Vital Therapies.

DB:10V PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:VTL Share Price ÷ EPS (both in USD)

= 0.83 ÷ -0.86

-0.97x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Vital Therapies is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Vital Therapies is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Vital Therapies's expected growth come at a high price?
Raw Data
DB:10V PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.97x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 21 Publicly-Listed Biotechs Companies 1.32x
Germany Market PEG Ratio Median Figure of 273 Publicly-Listed Companies 1.49x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Vital Therapies, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Vital Therapies's assets?
Raw Data
DB:10V PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $0.21
NasdaqGS:VTL Share Price * NasdaqGS (2019-04-12) in USD $0.83
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.47x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.84x
DB:10V PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:VTL Share Price ÷ Book Value per Share (both in USD)

= 0.83 ÷ 0.21

3.89x

* Primary Listing of Vital Therapies.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Vital Therapies is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Vital Therapies's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Vital Therapies has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Vital Therapies expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Vital Therapies has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
47.8%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Vital Therapies expected to grow at an attractive rate?
  • Unable to compare Vital Therapies's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Vital Therapies's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare Vital Therapies's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:10V Future Growth Rates Data Sources
Data Point Source Value (per year)
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.8%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 27.2%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.8%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:10V Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 week ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:10V Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
DB:10V Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 -34 -37
2018-12-31 -43 -41
2018-09-30 -48 -54
2018-06-30 -45 -54
2018-03-31 -43 -54
2017-12-31 -40 -52
2017-09-30 -40 -49
2017-06-30 -38 -47
2017-03-31 -37 -44
2016-12-31 -36 -41
2016-09-30 -36 -39
2016-06-30 -40 -41

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Vital Therapies is high growth as no earnings estimate data is available.
  • Unable to determine if Vital Therapies is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:10V Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 week ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Vital Therapies Company Filings, last reported 1 week ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:10V Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
DB:10V Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -0.86
2018-12-31 -0.98
2018-09-30 -1.27
2018-06-30 -1.28
2018-03-31 -1.27
2017-12-31 -1.31
2017-09-30 -1.32
2017-06-30 -1.35
2017-03-31 -1.38
2016-12-31 -1.31
2016-09-30 -1.28
2016-06-30 -1.44

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Vital Therapies will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Vital Therapies's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Vital Therapies's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Vital Therapies's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Vital Therapies's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Vital Therapies has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Vital Therapies performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Vital Therapies's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Vital Therapies does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Vital Therapies's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Vital Therapies's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Vital Therapies's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Vital Therapies Company Filings, last reported 1 week ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:10V Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 -36.58 11.94 15.16
2018-12-31 -41.48 13.59 24.83
2018-09-30 -53.60 14.44 35.00
2018-06-30 -54.14 14.93 38.70
2018-03-31 -53.86 13.39 39.87
2017-12-31 -52.08 12.12 39.34
2017-09-30 -49.22 11.69 38.01
2017-06-30 -46.92 11.51 35.79
2017-03-31 -43.98 11.48 32.82
2016-12-31 -40.97 11.22 30.05
2016-09-30 -39.09 11.32 27.53
2016-06-30 -41.22 11.24 29.70
2016-03-31 -46.85 12.08 34.39
2015-12-31 -52.02 12.35 39.77
2015-09-30 -56.12 12.41 43.84
2015-06-30 -56.62 12.29 44.43
2015-03-31 -57.76 11.27 42.01
2014-12-31 -56.82 10.86 39.48
2014-09-30 -55.32 10.33 36.24
2014-06-30 -51.56 10.77 32.16
2014-03-31 -42.57 10.78 27.57
2013-12-31 -39.09 9.62 21.79
2013-09-30 -27.87 8.14 16.51
2013-06-30 -21.53 6.26 11.61
2013-03-31 -15.98 4.63 7.79
2012-12-31 -7.64 4.48 5.10

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Vital Therapies has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Vital Therapies has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Vital Therapies improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Vital Therapies's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Vital Therapies has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Vital Therapies's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Vital Therapies's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Vital Therapies is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Vital Therapies has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Vital Therapies's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Vital Therapies has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Vital Therapies Company Filings, last reported 1 week ago.

DB:10V Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 9.05 0.00 9.60
2018-12-31 12.43 0.00 13.32
2018-09-30 14.25 0.00 17.80
2018-06-30 26.45 0.00 31.12
2018-03-31 37.30 0.00 43.65
2017-12-31 50.04 0.00 56.90
2017-09-30 62.08 0.00 66.39
2017-06-30 73.34 0.00 76.15
2017-03-31 84.43 0.00 86.64
2016-12-31 58.45 0.00 59.99
2016-09-30 67.76 0.00 68.09
2016-06-30 74.15 0.00 73.60
2016-03-31 78.05 0.00 77.88
2015-12-31 82.33 0.00 83.42
2015-09-30 58.68 0.00 59.75
2015-06-30 69.74 0.00 71.95
2015-03-31 83.78 0.00 88.26
2014-12-31 97.56 0.00 102.24
2014-09-30 77.05 0.00 79.09
2014-06-30 89.16 0.00 90.84
2014-03-31 46.70 0.00 46.04
2013-12-31 38.82 0.00 38.19
2013-09-30 29.98 0.13 31.16
2013-06-30 36.63 0.19 41.44
2013-03-31 10.93 0.00 16.15
2012-12-31 18.54 0.00 18.47
  • Vital Therapies has no debt.
  • Vital Therapies had no debt 5 years ago.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Vital Therapies has less than a year of cash runway based on current free cash flow.
  • Vital Therapies has less than a year of cash runway if free cash flow continues to grow at historical rates of 1.3% each year.
X
Financial health checks
We assess Vital Therapies's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Vital Therapies has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Vital Therapies's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Vital Therapies dividends.
If you bought €2,000 of Vital Therapies shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Vital Therapies's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Vital Therapies's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:10V Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 0.8%
Germany Market Average Dividend Yield Market Cap Weighted Average of 325 Stocks 3.1%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.5%
Germany Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:10V Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Vital Therapies has not reported any payouts.
  • Unable to verify if Vital Therapies's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Vital Therapies's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Vital Therapies has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Vital Therapies's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Vital Therapies afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Vital Therapies has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Vital Therapies's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Duane Nash
COMPENSATION $753,152
AGE 47
TENURE AS CEO 0.3 years
CEO Bio

Dr. Duane D. Nash, M.D., J.D., M.B.A. has been the President of Vital Therapies, Inc. since March 08, 2016 and has been its Chief Executive Officer and Director since January 26, 2019. Dr. Nash served as the Chief Business Officer at Vital Therapies, Inc. from March 19, 2012 to March 8, 2016 and also served as its Executive Vice President from May 2013 to March 2016. He served as Medical Director at Vital Therapies, Inc. from March 19, 2012 to May 2013. He served as Senior Vice President in Equity Research at Wedbush PacGrow Life Sciences. He served as Senior Vice President at Wedbush Securities Inc., Research Division from March 2009 to March 2012. He used to cover cardiac, hepatic and regenerative medicines at the firm. He was a Healthcare Research Analyst at Pacific Growth Equities, LLC, Research Division from April 2008 through March 2009. He was an Independent Director of Akebia Therapeutics, Inc. since May 2013 until December 12, 2018. He served as a Director of Aerpio Pharmaceuticals, Inc. (formerly Aerpio Therapeutics, Inc.) from September 2012 to March 2017. He has practiced as an Attorney from November 2002 to February 2008. He was employed at Davis Polk & Wardwell LLP, where he practiced intellectual property litigation, as well as patent evaluation and strategy in the merger and acquisition context. He worked at two other Bay Area law firms and also completed his internship in General Surgery at the University of California at San Francisco, where he served as a member of the liver transplant team. According to STARMINE and Thomson Reuters, Dr. Nash is ranked first among 66 equity research analysts nationwide who publish in the biotechnology market, based on prior 12 month return on recommendations. He is a California-licensed Physician at Medical Board of California and also an inactive member of the California Bar. Dr. Nash holds his J.D. from the University of California at Berkeley, his M.D. from Dartmouth Medical School, an M.B.A. from the University of Oxford and a B.A. in Biology from Williams College.

CEO Compensation
  • Duane's compensation has been consistent with company performance over the past year.
  • Duane's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Vital Therapies management team in years:

2.4
Average Tenure
61.5
Average Age
  • The tenure for the Vital Therapies management team is about average.
Management Team

Duane Nash

TITLE
CEO, President & Director
COMPENSATION
$753K
AGE
47
TENURE
0.3 yrs

Robert Ashley

TITLE
Executive VP & Chief Scientific Officer
COMPENSATION
$704K
AGE
60
TENURE
0.4 yrs

Mike Swanson

TITLE
Executive VP
COMPENSATION
$777K
AGE
63
TENURE
5.7 yrs

John Dunn

TITLE
General Counsel & Secretary
COMPENSATION
$701K
AGE
66
TENURE
4.4 yrs
Board of Directors Tenure

Average tenure and age of the Vital Therapies board of directors in years:

2.7
Average Tenure
56
Average Age
  • The average tenure for the Vital Therapies board of directors is less than 3 years, this suggests a new board.
Board of Directors

Faheem Hasnain

TITLE
Chairman of the Board & Lead Director
COMPENSATION
$235K
AGE
60
TENURE
1.6 yrs

Duane Nash

TITLE
CEO, President & Director
COMPENSATION
$753K
AGE
47
TENURE
0.3 yrs

Lowell Sears

TITLE
Independent Director
COMPENSATION
$182K
AGE
67
TENURE
5.9 yrs

Cheryl Cohen

TITLE
Independent Director
COMPENSATION
$174K
AGE
52
TENURE
3.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
25. Sep 18 Sell Errol Halperin Individual 25. Sep 18 25. Sep 18 -99,417 €0.25 €-24,499
24. Sep 18 Sell Jean-Jacques Bienaimé Individual 24. Sep 18 24. Sep 18 -26,619 €0.26 €-6,793
21. Sep 18 Sell Douglas Godshall Individual 19. Sep 18 19. Sep 18 -69,375 €0.30 €-20,720
18. Sep 18 Sell Muneer Satter Individual 13. Sep 18 17. Sep 18 -7,132,277 €0.42 €-2,222,859
18. Sep 18 Sell Faheem Hasnain Individual 13. Sep 18 13. Sep 18 -177,443 €0.37 €-66,516
18. Sep 18 Sell Jean-Jacques Bienaimé Individual 13. Sep 18 13. Sep 18 -20,000 €0.40 €-8,049
14. Sep 18 Sell Cheryl Cohen Individual 12. Sep 18 12. Sep 18 -3,500 €0.47 €-1,654
X
Management checks
We assess Vital Therapies's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Vital Therapies has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Vital Therapies, Inc., a biotherapeutic company, focuses on developing cell-based therapies for the treatment of acute forms of liver failure. The company was formerly known as Vitagen Acquisition Corp. and changed its name to Vital Therapies, Inc. in June 2003. Vital Therapies, Inc. was founded in 2003 and is based in San Diego, California.

Details
Name: Vital Therapies, Inc.
10V
Exchange: DB
Founded: 2003
$31,076,942
42,369,694
Website: http://www.vitaltherapies.com
Address: Vital Therapies, Inc.
15222-B Avenue of Science,
San Diego,
California, 92128,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS VTL Common Stock Nasdaq Global Select US USD 17. Apr 2014
DB 10V Common Stock Deutsche Boerse AG DE EUR 17. Apr 2014
LSE 0LQI Common Stock London Stock Exchange GB USD 17. Apr 2014
Number of employees
Current staff
Staff numbers
10
Vital Therapies employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/12 22:24
End of day share price update: 2019/04/12 00:00
Last estimates confirmation: 2018/03/13
Last earnings filing: 2019/04/10
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.